Search

Your search keyword '"Kulis, Marta' showing total 353 results
Start Over Author "Kulis, Marta
353 results on '"Kulis, Marta'

2. KDM6A regulates immune response genes in multiple myeloma

Author

Dupéré-Richer, Daphné, Riva, Alberto, Barwick, Benjamin G., Maji, Sayantan, Casellas Román, Heidi, Li, Jianping, De, Umasankar, Sobh, Amin, Quickstad, Gabrielle, Piper, Crissandra, Kulis, Marta, Ezponda, Teresa, Martín-Subero, José Ignacio, Tonon, Giovanni, Zhang, Weizhou, Mitsiades, Constantine S., Boise, Lawrence H., Bennett, Richard L., and Licht, Jonathan D.

Published
2024
Full Text
View/download PDF

3. Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma

Author

Sureda-Gómez, Marta, Balsas, Patricia, Rodríguez, Marta-Leonor, Nadeu, Ferran, De Bolòs, Anna, Eguileor, Álvaro, Kulis, Marta, Castellano, Giancarlo, López, Cristina, Giné, Eva, Demajo, Santiago, Jares, Pedro, Martín-Subero, José I., Beà, Silvia, Campo, Elias, and Amador, Virginia

Published
2023
Full Text
View/download PDF

5. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

Author

Nadeu, Ferran, Royo, Romina, Massoni-Badosa, Ramon, Playa-Albinyana, Heribert, Garcia-Torre, Beatriz, Duran-Ferrer, Martí, Dawson, Kevin J., Kulis, Marta, Diaz-Navarro, Ander, Villamor, Neus, Melero, Juan L., Chapaprieta, Vicente, Dueso-Barroso, Ana, Delgado, Julio, Moia, Riccardo, Ruiz-Gil, Sara, Marchese, Domenica, Giró, Ariadna, Verdaguer-Dot, Núria, Romo, Mónica, Clot, Guillem, Rozman, Maria, Frigola, Gerard, Rivas-Delgado, Alfredo, Baumann, Tycho, Alcoceba, Miguel, González, Marcos, Climent, Fina, Abrisqueta, Pau, Castellví, Josep, Bosch, Francesc, Aymerich, Marta, Enjuanes, Anna, Ruiz-Gaspà, Sílvia, López-Guillermo, Armando, Jares, Pedro, Beà, Sílvia, Capella-Gutierrez, Salvador, Gelpí, Josep Ll., López-Bigas, Núria, Torrents, David, Campbell, Peter J., Gut, Ivo, Rossi, Davide, Gaidano, Gianluca, Puente, Xose S., Garcia-Roves, Pablo M., Colomer, Dolors, Heyn, Holger, Maura, Francesco, Martín-Subero, José I., and Campo, Elías

Published
2022
Full Text
View/download PDF

7. Remission of obesity and insulin resistance is not sufficient to restore mitochondrial homeostasis in visceral adipose tissue

Author

Gonzalez-Franquesa, Alba, Gama-Perez, Pau, Kulis, Marta, Szczepanowska, Karolina, Dahdah, Norma, Moreno-Gomez, Sonia, Latorre-Pellicer, Ana, Fernández-Ruiz, Rebeca, Aguilar-Mogas, Antoni, Hoffman, Anne, Monelli, Erika, Samino, Sara, Miró-Blanch, Joan, Oemer, Gregor, Duran, Xavier, Sanchez-Rebordelo, Estrella, Schneeberger, Marc, Obach, Merce, Montane, Joel, Castellano, Giancarlo, Chapaprieta, Vicente, Sun, Wenfei, Navarro, Lourdes, Prieto, Ignacio, Castaño, Carlos, Novials, Anna, Gomis, Ramon, Monsalve, Maria, Claret, Marc, Graupera, Mariona, Soria, Guadalupe, Wolfrum, Christian, Vendrell, Joan, Fernández-Veledo, Sonia, Enríquez, Jose Antonio, Carracedo, Angel, Perales, José Carlos, Nogueiras, Rubén, Herrero, Laura, Trifunovic, Aleksandra, Keller, Markus A., Yanes, Oscar, Sales-Pardo, Marta, Guimerà, Roger, Blüher, Matthias, Martín-Subero, José Ignacio, and Garcia-Roves, Pablo M.

Published
2022
Full Text
View/download PDF

9. Epigenetic, psychological, and EEG changes after a 1-week retreat based on mindfulness and compassion for stress reduction in healthy adults: Study protocol of a cross-over randomized controlled trial.

Author

Gustavo G Diez, Ignacio Martin-Subero, Rosaria M Zangri, Marta Kulis, Catherine Andreu, Ivan Blanco, Pablo Roca, Pablo Cuesta, Carola García, Jesús Garzón, Carlos Herradón, Miguel Riutort, Shishir Baliyan, César Venero, and Carmelo Vázquez

Subjects
Medicine, Science
Abstract

IntroductionThe main objective of the study will be to evaluate the effects of two widely used standardized mindfulness-based programs [Mindfulness-Based Stress Reduction (MBSR) and Compassion Cultivation Training (CCT)], on epigenetic, neurobiological, psychological, and physiological variables.MethodsThe programs will be offered in an intensive retreat format in a general population sample of healthy volunteer adults. During a 7-day retreat, participants will receive MBSR and CCT in a crossover design where participants complete both programs in random order. After finishing their first 3-day training with one of the two programs, participants will be assigned to the second 3-day training with the second program. The effects of the MBSR and CCT programs, and their combination, will be measured by epigenetic changes (i.e., DNA methylation biomarkers), neurobiological and psychophysiological measures (i.e., EEG resting state, EKG, respiration patterns, and diurnal cortisol slopes), self-report questionnaires belonging to different psychological domains (i.e., mindfulness, compassion, well-being, distress, and general functioning), and stress tasks (i.e., an Arithmetic Stress Test and the retrieval of negative autobiographical memories). These measures will be collected from both groups on the mornings of day 1 (pre-program), day 4 (after finishing the first program and before beginning the second program), and day 7 (post-second program). We will conduct a 3-month and a 12-month follow-up using only the set of self-report measures.DiscussionThis study aims to shed light on the neurobiological and psychological mechanisms linked to meditation and compassion in the general population. The protocol was registered at clinicaltrials.gov (Identifier: NCT05516355; August 23, 2022).

Published
2023
Full Text
View/download PDF

11. Remission of obesity and insulin resistance is not sufficient to restore mitochondrial homeostasis in visceral adipose tissue

Author

Alba Gonzalez-Franquesa, Pau Gama-Perez, Marta Kulis, Karolina Szczepanowska, Norma Dahdah, Sonia Moreno-Gomez, Ana Latorre-Pellicer, Rebeca Fernández-Ruiz, Antoni Aguilar-Mogas, Anne Hoffman, Erika Monelli, Sara Samino, Joan Miró-Blanch, Gregor Oemer, Xavier Duran, Estrella Sanchez-Rebordelo, Marc Schneeberger, Merce Obach, Joel Montane, Giancarlo Castellano, Vicente Chapaprieta, Wenfei Sun, Lourdes Navarro, Ignacio Prieto, Carlos Castaño, Anna Novials, Ramon Gomis, Maria Monsalve, Marc Claret, Mariona Graupera, Guadalupe Soria, Christian Wolfrum, Joan Vendrell, Sonia Fernández-Veledo, Jose Antonio Enríquez, Angel Carracedo, José Carlos Perales, Rubén Nogueiras, Laura Herrero, Aleksandra Trifunovic, Markus A. Keller, Oscar Yanes, Marta Sales-Pardo, Roger Guimerà, Matthias Blüher, José Ignacio Martín-Subero, and Pablo M. Garcia-Roves

Subjects
Obesity, Metabolic plasticity, Visceral adipose tissue, Mitochondrial dysfunction, Exercise, Caloric restriction, Medicine (General), R5-920, Biology (General), QH301-705.5
Abstract

Metabolic plasticity is the ability of a biological system to adapt its metabolic phenotype to different environmental stressors. We used a whole-body and tissue-specific phenotypic, functional, proteomic, metabolomic and transcriptomic approach to systematically assess metabolic plasticity in diet-induced obese mice after a combined nutritional and exercise intervention. Although most obesity and overnutrition-related pathological features were successfully reverted, we observed a high degree of metabolic dysfunction in visceral white adipose tissue, characterized by abnormal mitochondrial morphology and functionality. Despite two sequential therapeutic interventions and an apparent global healthy phenotype, obesity triggered a cascade of events in visceral adipose tissue progressing from mitochondrial metabolic and proteostatic alterations to widespread cellular stress, which compromises its biosynthetic and recycling capacity. In humans, weight loss after bariatric surgery showed a transcriptional signature in visceral adipose tissue similar to our mouse model of obesity reversion. Overall, our data indicate that obesity prompts a lasting metabolic fingerprint that leads to a progressive breakdown of metabolic plasticity in visceral adipose tissue.

Published
2022
Full Text
View/download PDF

12. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma

Author

Carrasco-Leon, Arantxa, Ezponda, Teresa, Meydan, Cem, Valcárcel, Luis V., Ordoñez, Raquel, Kulis, Marta, Garate, Leire, Miranda, Estíbaliz, Segura, Victor, Guruceaga, Elisabeth, Vilas-Zornoza, Amaia, Alignani, Diego, Pascual, Marién, Amundarain, Ane, Castro-Labrador, Laura, Martín-Uriz, Patxi San, El-Omri, Halima, Taha, Ruba Y., Calasanz, Maria J., Planes, Francisco J., Paiva, Bruno, Mason, Christopher E., San Miguel, Jesús F., Martin-Subero, José I., Melnick, Ari, Prosper, Felipe, and Agirre, Xabier

Published
2021
Full Text
View/download PDF

13. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes

Author

Nadeu, Ferran, Martin-Garcia, David, Clot, Guillem, Díaz-Navarro, Ander, Duran-Ferrer, Martí, Navarro, Alba, Vilarrasa-Blasi, Roser, Kulis, Marta, Royo, Romina, Gutiérrez-Abril, Jesús, Valdés-Mas, Rafael, López, Cristina, Chapaprieta, Vicente, Puiggros, Montserrat, Castellano, Giancarlo, Costa, Dolors, Aymerich, Marta, Jares, Pedro, Espinet, Blanca, Muntañola, Ana, Ribera-Cortada, Inmaculada, Siebert, Reiner, Colomer, Dolors, Torrents, David, Gine, Eva, López-Guillermo, Armando, Küppers, Ralf, Martin-Subero, Jose I., Puente, Xose S., Beà, Sílvia, and Campo, Elias

Published
2020
Full Text
View/download PDF

14. KDM6A Regulates Immune Response Genes in Multiple Myeloma

Author

Dupere-Richer, Daphne, primary, Riva, Alberto, additional, Maji, Sayantan, additional, Barwick, Benjamin Gabriel, additional, Casella, Heidi, additional, Sobh, Amin, additional, Quickstad, Gabrielle, additional, Li, Jianping, additional, de, umasankar, additional, Piper, Crissandra, additional, Kulis, Marta, additional, Ezponda, Teresa, additional, Martin-Subero, Ignacio, additional, Tonon, Giovanni, additional, Zhang, Weizhou, additional, Mitsiades, Constantine, additional, Boise, Lawrence H., additional, Bennett, Richard L, additional, and Licht, Jonathan D, additional

Published
2024
Full Text
View/download PDF

15. Quantitative comparison of DNA methylation assays for biomarker development and clinical applications

Author

Bock, Christoph, Halbritter, Florian, Carmona, Francisco J, Tierling, Sascha, Datlinger, Paul, Assenov, Yassen, Berdasco, Maria, Bergmann, Anke K, Booher, Keith, Busato, Florence, Campan, Mihaela, Dahl, Christina, Dahmcke, Christina M, Diep, Dinh, Fernandez, Agustin F, Gerhauser, Clarissa, Haake, Andrea, Heilmann, Katharina, Holcomb, Thomas, Hussmann, Dianna, Ito, Mitsuteru, Klaever, Ruth, Kreutz, Martin, Kulis, Marta, Lopez, Virginia, Nair, Shalima S, Paul, Dirk S, Plongthongkum, Nongluk, Qu, Wenjia, Queiros, Ana C, Reinicke, Frank, Sauter, Guido, Schlomm, Thorsten, Statham, Aaron, Stirzaker, Clare, Strogantsev, Ruslan, Urdinguio, Rocio G, Walter, Kimberly, Weichenhan, Dieter, Weisenberger, Daniel J, Beck, Stephan, Clark, Susan J, Esteller, Manel, Ferguson-Smith, Anne C, Fraga, Mario F, Guldberg, Per, Hansen, Lise Lotte, Laird, Peter W, Martin-Subero, Jose I, Nygren, Anders OH, Peist, Ralf, Plass, Christoph, Shames, David S, Siebert, Reiner, Sun, Xueguang, Tost, Jorg, Walter, Joern, and Zhang, Kun

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Clinical Sciences, Genetics, Algorithms, DNA, DNA Methylation, DNA Modification Methylases, Genetic Markers, High-Throughput Nucleotide Sequencing, High-Throughput Screening Assays, Promoter Regions, Genetic, Reproducibility of Results, Sensitivity and Specificity, BLUEPRINT consortium
Abstract

DNA methylation patterns are altered in numerous diseases and often correlate with clinically relevant information such as disease subtypes, prognosis and drug response. With suitable assays and after validation in large cohorts, such associations can be exploited for clinical diagnostics and personalized treatment decisions. Here we describe the results of a community-wide benchmarking study comparing the performance of all widely used methods for DNA methylation analysis that are compatible with routine clinical use. We shipped 32 reference samples to 18 laboratories in seven different countries. Researchers in those laboratories collectively contributed 21 locus-specific assays for an average of 27 predefined genomic regions, as well as six global assays. We evaluated assay sensitivity on low-input samples and assessed the assays' ability to discriminate between cell types. Good agreement was observed across all tested methods, with amplicon bisulfite sequencing and bisulfite pyrosequencing showing the best all-round performance. Our technology comparison can inform the selection, optimization and use of DNA methylation assays in large-scale validation studies, biomarker development and clinical diagnostics.

Published
2016

16. Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation

Author

Roser Vilarrasa-Blasi, Paula Soler-Vila, Núria Verdaguer-Dot, Núria Russiñol, Marco Di Stefano, Vicente Chapaprieta, Guillem Clot, Irene Farabella, Pol Cuscó, Marta Kulis, Xabier Agirre, Felipe Prosper, Renée Beekman, Silvia Beà, Dolors Colomer, Hendrik G. Stunnenberg, Ivo Gut, Elias Campo, Marc A. Marti-Renom, and José Ignacio Martin-Subero

Subjects
Science
Abstract

The dynamics of genome architecture during human cell differentiation and upon neoplastic transformation remain poorly characterized. Here, the authors integrate in situ Hi-C and nine additional omic layers to characterize the dynamic changes in 3D genome architecture during normal B cell differentiation and in neoplastic cells from chronic lymphocytic leukemia and mantle cell lymphoma patients.

Published
2021
Full Text
View/download PDF

17. Sampling time-dependent artifacts in single-cell genomics studies

Author

Ramon Massoni-Badosa, Giovanni Iacono, Catia Moutinho, Marta Kulis, Núria Palau, Domenica Marchese, Javier Rodríguez-Ubreva, Esteban Ballestar, Gustavo Rodriguez-Esteban, Sara Marsal, Marta Aymerich, Dolors Colomer, Elias Campo, Antonio Julià, José Ignacio Martín-Subero, and Holger Heyn

Subjects
Single-cell, Biobank, RNA sequencing, Peripheral blood mononuclear cells, PBMC, Chronic lymphocytic leukemia, Biology (General), QH301-705.5, Genetics, QH426-470
Abstract

Abstract Robust protocols and automation now enable large-scale single-cell RNA and ATAC sequencing experiments and their application on biobank and clinical cohorts. However, technical biases introduced during sample acquisition can hinder solid, reproducible results, and a systematic benchmarking is required before entering large-scale data production. Here, we report the existence and extent of gene expression and chromatin accessibility artifacts introduced during sampling and identify experimental and computational solutions for their prevention.

Published
2020
Full Text
View/download PDF

18. The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome

Author

Duran-Ferrer, Martí, Clot, Guillem, Nadeu, Ferran, Beekman, Renée, Baumann, Tycho, Nordlund, Jessica, Marincevic-Zuniga, Yanara, Lönnerholm, Gudmar, Rivas-Delgado, Alfredo, Martín, Silvia, Ordoñez, Raquel, Castellano, Giancarlo, Kulis, Marta, Queirós, Ana C., Lee, Seung-Tae, Wiemels, Joseph, Royo, Romina, Puiggrós, Montserrat, Lu, Junyan, Giné, Eva, Beà, Sílvia, Jares, Pedro, Agirre, Xabier, Prosper, Felipe, López-Otín, Carlos, Puente, Xosé S., Oakes, Christopher C., Zenz, Thorsten, Delgado, Julio, López-Guillermo, Armando, Campo, Elías, and Martín-Subero, José Ignacio

Published
2020
Full Text
View/download PDF

19. Whole-genome fingerprint of the DNA methylome during human B cell differentiation

Author

Kulis, Marta, Merkel, Angelika, Heath, Simon, Queirós, Ana C, Schuyler, Ronald P, Castellano, Giancarlo, Beekman, Renée, Raineri, Emanuele, Esteve, Anna, Clot, Guillem, Verdaguer-Dot, Néria, Duran-Ferrer, Martí, Russiñol, Nuria, Vilarrasa-Blasi, Roser, Ecker, Simone, Pancaldi, Vera, Rico, Daniel, Agueda, Lidia, Blanc, Julie, Richardson, David, Clarke, Laura, Datta, Avik, Pascual, Marien, Agirre, Xabier, Prosper, Felipe, Alignani, Diego, Paiva, Bruno, Caron, Gersende, Fest, Thierry, Muench, Marcus O, Fomin, Marina E, Lee, Seung-Tae, Wiemels, Joseph L, Valencia, Alfonso, Gut, Marta, Flicek, Paul, Stunnenberg, Hendrik G, Siebert, Reiner, Küppers, Ralf, Gut, Ivo G, Campo, Elías, and Martín-Subero, José I

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Genetics, Human Genome, B-Lymphocytes, Base Sequence, Cell Differentiation, Cells, Cultured, CpG Islands, DNA Methylation, Epigenesis, Genetic, Gene Expression Regulation, Leukemic, Genome, Human, Humans, Leukemia, B-Cell, Sequence Analysis, DNA, Medical and Health Sciences, Developmental Biology, Agricultural biotechnology, Bioinformatics and computational biology
Abstract

We analyzed the DNA methylome of ten subpopulations spanning the entire B cell differentiation program by whole-genome bisulfite sequencing and high-density microarrays. We observed that non-CpG methylation disappeared upon B cell commitment, whereas CpG methylation changed extensively during B cell maturation, showing an accumulative pattern and affecting around 30% of all measured CpG sites. Early differentiation stages mainly displayed enhancer demethylation, which was associated with upregulation of key B cell transcription factors and affected multiple genes involved in B cell biology. Late differentiation stages, in contrast, showed extensive demethylation of heterochromatin and methylation gain at Polycomb-repressed areas, and genes with apparent functional impact in B cells were not affected. This signature, which has previously been linked to aging and cancer, was particularly widespread in mature cells with an extended lifespan. Comparing B cell neoplasms with their normal counterparts, we determined that they frequently acquire methylation changes in regions already undergoing dynamic methylation during normal B cell differentiation.

Published
2015

20. Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation

Author

Vilarrasa-Blasi, Roser, Soler-Vila, Paula, Verdaguer-Dot, Núria, Russiñol, Núria, Di Stefano, Marco, Chapaprieta, Vicente, Clot, Guillem, Farabella, Irene, Cuscó, Pol, Kulis, Marta, Agirre, Xabier, Prosper, Felipe, Beekman, Renée, Beà, Silvia, Colomer, Dolors, Stunnenberg, Hendrik G., Gut, Ivo, Campo, Elias, Marti-Renom, Marc A., and Martin-Subero, José Ignacio

Published
2021
Full Text
View/download PDF

21. Correction: Epigenetic, psychological, and EEG changes after a 1-week retreat based on mindfulness and compassion for stress reduction in healthy adults: Study protocol of a cross-over randomized controlled trial

Author

Diez, Gustavo G., primary, Martin-Subero, Ignacio, additional, Zangri, Rosaria M., additional, Kulis, Marta, additional, Andreu, Catherine, additional, Blanco, Ivan, additional, Roca, Pablo, additional, Cuesta, Pablo, additional, García, Carola, additional, Garzón, Jesús, additional, Herradón, Carlos, additional, Riutort, Miguel, additional, Baliyan, Shishir, additional, Venero, César, additional, and Vázquez, Carmelo, additional

Published
2024
Full Text
View/download PDF

22. An atlas of cells in the human tonsil

Author

Massoni-Badosa, Ramon, primary, Aguilar-Fernández, Sergio, additional, Nieto, Juan C., additional, Soler-Vila, Paula, additional, Elosua-Bayes, Marc, additional, Marchese, Domenica, additional, Kulis, Marta, additional, Vilas-Zornoza, Amaia, additional, Bühler, Marco Matteo, additional, Rashmi, Sonal, additional, Alsinet, Clara, additional, Caratù, Ginevra, additional, Moutinho, Catia, additional, Ruiz, Sara, additional, Lorden, Patricia, additional, Lunazzi, Giulia, additional, Colomer, Dolors, additional, Frigola, Gerard, additional, Blevins, Will, additional, Romero-Rivero, Lucia, additional, Jiménez-Martínez, Víctor, additional, Vidal, Anna, additional, Mateos-Jaimez, Judith, additional, Maiques-Diaz, Alba, additional, Ovejero, Sara, additional, Moreaux, Jérôme, additional, Palomino, Sara, additional, Gomez-Cabrero, David, additional, Agirre, Xabier, additional, Weniger, Marc A., additional, King, Hamish W., additional, Garner, Lucy C., additional, Marini, Federico, additional, Cervera-Paz, Francisco Javier, additional, Baptista, Peter M., additional, Vilaseca, Isabel, additional, Rosales, Cecilia, additional, Ruiz-Gaspà, Silvia, additional, Talks, Benjamin, additional, Sidhpura, Keval, additional, Pascual-Reguant, Anna, additional, Hauser, Anja E., additional, Haniffa, Muzlifah, additional, Prosper, Felipe, additional, Küppers, Ralf, additional, Gut, Ivo Glynne, additional, Campo, Elias, additional, Martin-Subero, José Ignacio, additional, and Heyn, Holger, additional

Published
2024
Full Text
View/download PDF

23. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

Author

Syrykh, Charlotte, primary, Pons-Brun, Berta, additional, Russiñol, Núria, additional, Playa-Albinyana, Heribert, additional, Baumann, Tycho, additional, Duran-Ferrer, Martí, additional, Kulis, Marta, additional, Carbó-Meix, Anna, additional, Mozas, Pablo, additional, Alcoceba, Miguel, additional, González, Marcos, additional, Navarro-Bailón, Almudena, additional, Colado, Enrique, additional, Payer, Ángel R., additional, Aymerich, Marta, additional, Terol, María J., additional, Lu, Junyan, additional, Knisbacher, Binyamin A., additional, Hahn, Cynthia K., additional, Ruiz-Gaspà, Sílvia, additional, Enjuanes, Anna, additional, Wu, Catherine J., additional, Getz, Gad, additional, Zenz, Thorsten, additional, López-Guillermo, Armando, additional, Martín-Subero, José I., additional, Colomer, Dolors, additional, Delgado, Julio, additional, Campo, Elías, additional, and Nadeu, Ferran, additional

Published
2023
Full Text
View/download PDF

24. Activating NSD2 Mutations Drive Oncogenic Reprogramming By Disturbing Epigenetic Landscape in Mantle Cell Lymphoma

Author

Li, Jianping, primary, Kulis, Marta, additional, Riva, Alberto, additional, Casellas Román, Heidi, additional, Dupere-Richer, Daphne, additional, Clerio, Monica, additional, Trejo, Melanie L., additional, Menes, Michael, additional, Lamberto, Anthony Joseph, additional, Sobh, Amin, additional, Kaestner, Charlotte Leonie, additional, Bennett, Richard Lynn, additional, Martin Subero, Iñaki I., additional, and Licht, Jonathan D., additional

Published
2023
Full Text
View/download PDF

25. Epigenetic, psychological, and EEG changes after a 1-week retreat based on mindfulness and compassion for stress reduction in healthy adults: Study protocol of a cross-over randomized controlled trial

Author

Diez, Gustavo G., primary, Martin-Subero, Ignacio, additional, Zangri, Rosaria M., additional, Kulis, Marta, additional, Andreu, Catherine, additional, Blanco, Ivan, additional, Roca, Pablo, additional, Cuesta, Pablo, additional, García, Carola, additional, Garzón, Jesús, additional, Herradón, Carlos, additional, Riutort, Miguel, additional, Baliyan, Shishir, additional, Venero, César, additional, and Vázquez, Carmelo, additional

Published
2023
Full Text
View/download PDF

26. Sampling time-dependent artifacts in single-cell genomics studies

Author

Massoni-Badosa, Ramon, Iacono, Giovanni, Moutinho, Catia, Kulis, Marta, Palau, Núria, Marchese, Domenica, Rodríguez-Ubreva, Javier, Ballestar, Esteban, Rodriguez-Esteban, Gustavo, Marsal, Sara, Aymerich, Marta, Colomer, Dolors, Campo, Elias, Julià, Antonio, Martín-Subero, José Ignacio, and Heyn, Holger

Published
2020
Full Text
View/download PDF

27. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia

Author

Beekman, Renée, Chapaprieta, Vicente, Russiñol, Núria, Vilarrasa-Blasi, Roser, Verdaguer-Dot, Núria, Martens, Joost H. A., Duran-Ferrer, Martí, Kulis, Marta, Serra, François, Javierre, Biola M., Wingett, Steven W., Clot, Guillem, Queirós, Ana C., Castellano, Giancarlo, Blanc, Julie, Gut, Marta, Merkel, Angelika, Heath, Simon, Vlasova, Anna, Ullrich, Sebastian, Palumbo, Emilio, Enjuanes, Anna, Martín-García, David, Beà, Sílvia, Pinyol, Magda, Aymerich, Marta, Royo, Romina, Puiggros, Montserrat, Torrents, David, Datta, Avik, Lowy, Ernesto, Kostadima, Myrto, Roller, Maša, Clarke, Laura, Flicek, Paul, Agirre, Xabier, Prosper, Felipe, Baumann, Tycho, Delgado, Julio, López-Guillermo, Armando, Fraser, Peter, Yaspo, Marie-Laure, Guigó, Roderic, Siebert, Reiner, Martí-Renom, Marc A., Puente, Xose S., López-Otín, Carlos, Gut, Ivo, Stunnenberg, Hendrik G., Campo, Elias, and Martin-Subero, Jose I.

Published
2018
Full Text
View/download PDF

28. Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications

Author

Marta Kulis and Jose Ignacio Martin‐Subero

Subjects
Hematology
Abstract

Chronic lymphocytic leukaemia (CLL) is not only characterised by driver genetic alterations but by extensive epigenetic changes. Over the last decade, epigenomic studies have described the DNA methylome, chromatin accessibility, histone modifications and the three-dimensional (3D) genome architecture of CLL. Beyond its regulatory role, the DNA methylome contains imprints of the cellular origin and proliferative history of CLL cells. These two aspects are strong independent prognostic factors. Integrative analyses of chromatin marks have uncovered novel regulatory elements and altered transcription factor networks as non-genetic means mediating gene deregulation in CLL. Additionally, CLL cells display a disease-specific pattern of 3D genome interactions. From the technological perspective, we are currently witnessing a transition from bulk omics to single-cell analyses. This review aims at summarising the major findings from the epigenomics field as well as providing a prospect of the present and future of single-cell analyses in CLL.

Published
2022
Full Text
View/download PDF

30. Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated

Author

Nicolás Martínez-Calle, Marien Pascual, Raquel Ordoñez, Edurne San José Enériz, Marta Kulis, Estíbaliz Miranda, Elisabeth Guruceaga, Víctor Segura, María José Larráyoz, Beatriz Bellosillo, María José Calasanz, Carles Besses, José Rifón, José I. Martín-Subero, Xabier Agirre, and Felipe Prosper

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

In this study we interrogated the DNA methylome of myelofibrosis patients using high-density DNA methylation arrays. We detected 35,215 differentially methylated CpG, corresponding to 10,253 genes, between myelofibrosis patients and healthy controls. These changes were present both in primary and secondary myelofibrosis, which showed no differences between them. Remarkably, most differentially methylated CpG were located outside gene promoter regions and showed significant association with enhancer regions. This aberrant enhancer hypermethylation was negatively correlated with the expression of 27 genes in the myelofibrosis cohort. Of these, we focused on the ZFP36L1 gene and validated its decreased expression and enhancer DNA hypermethylation in an independent cohort of patients and myeloid cell-lines. In vitro reporter assay and 5’-azacitidine treatment confirmed the functional relevance of hyper-methylation of ZFP36L1 enhancer. Furthermore, in vitro rescue of ZFP36L1 expression had an impact on cell proliferation and induced apoptosis in SET-2 cell line indicating a possible role of ZFP36L1 as a tumor suppressor gene in myelofibrosis. Collectively, we describe the DNA methylation profile of myelofibrosis, identifying extensive changes in enhancer elements and revealing ZFP36L1 as a novel candidate tumor suppressor gene.

Published
2019
Full Text
View/download PDF

31. Impaired CpG Demethylation in Common Variable Immunodeficiency Associates With B Cell Phenotype and Proliferation Rate

Author

Lucía del Pino-Molina, Javier Rodríguez-Ubreva, Juan Torres Canizales, María Coronel-Díaz, Marta Kulis, José I. Martín-Subero, Mirjam van der Burg, Esteban Ballestar, and Eduardo López-Granados

Subjects
common variable immunodeficiency, B cells, CpG, DNA methylation, B cell phenotype, proliferation rate, Immunologic diseases. Allergy, RC581-607
Abstract

Common Variable Immunodeficiency (CVID) is characterized by impaired antibody production and poor terminal differentiation of the B cell compartment, yet its pathogenesis is still poorly understood. We first reported the occurrence of epigenetic alterations in CVID by high-throughput methylation analysis in CVID-discordant monozygotic twins. Data from a recent whole DNA methylome analysis throughout different stages of normal B cell differentiation allowed us to design a new experimental approach. We selected CpG sites for analysis based on two criteria: one, CpGs with potential association with the transcriptional status of relevant genes for B cell activation and differentiation; and two, CpGs that undergo significant demethylation from naïve to memory B cells in healthy individuals. DNA methylation was analyzed by bisulfite pyrosequencing of specific CpG sites in sorted naïve and memory B cell subsets from CVID patients and healthy donors. We observed impaired demethylation in two thirds of the selected CpGs in CVID memory B cells, in genes that govern B cell-specific processes or participate in B cell signaling. The degree of demethylation impairment associated with the extent of the memory B cell reduction. The impaired demethylation in such functionally relevant genes as AICDA in switched memory B cells correlated with a lower proliferative rate. Our new results reinforce the hypothesis of altered demethylation during B cell differentiation as a contributing pathogenic mechanism to the impairment of B cell function and maturation in CVID. In particular, deregulated epigenetic control of AICDA could play a role in the defective establishment of a post-germinal center B cell compartment in CVID.

Published
2019
Full Text
View/download PDF

32. Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage

Author

Queirós, Ana C., Beekman, Renée, Vilarrasa-Blasi, Roser, Duran-Ferrer, Martí, Clot, Guillem, Merkel, Angelika, Raineri, Emanuele, Russiñol, Nuria, Castellano, Giancarlo, Beà, Sílvia, Navarro, Alba, Kulis, Marta, Verdaguer-Dot, Núria, Jares, Pedro, Enjuanes, Anna, Calasanz, María José, Bergmann, Anke, Vater, Inga, Salaverría, Itziar, van de Werken, Harmen J.G., Wilson, Wyndham H., Datta, Avik, Flicek, Paul, Royo, Romina, Martens, Joost, Giné, Eva, Lopez-Guillermo, Armando, Stunnenberg, Hendrik G., Klapper, Wolfram, Pott, Christiane, Heath, Simon, Gut, Ivo G., Siebert, Reiner, Campo, Elías, and Martín-Subero, José I.

Published
2016
Full Text
View/download PDF

33. Robust CRISPR-Cas9 Genetic Editing of Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

Author

Mateos-Jaimez, Judith, Mangolini, Maurizio, Vidal, Anna, Kulis, Marta, Colomer, Dolors, Campo, Elias, Ringshausen, Ingo, Martin-Subero, Jose I, Maiques-Diaz, Alba, Ringshausen, Ingo [0000-0002-7247-311X], and Apollo - University of Cambridge Repository

Subjects
3201 Cardiovascular Medicine and Haematology, 32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis
Published
2023

34. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

Author

Fundación la Caixa, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Instituto de Salud Carlos III, European Commission, Generalitat de Catalunya, National Institutes of Health (US), National Cancer Institute (US), Centro de Investigación Biomédica en Red Cáncer (España), Ministerio de Universidades (España), Fundación Científica Asociación Española Contra el Cáncer, National Heart, Lung, and Blood Institute (US), American Association for Cancer Research, Lady Tata Memorial Trust, Institución Catalana de Investigación y Estudios Avanzados, Centro Esther Koplowitz, Syrykh, Charlotte, Pons-Brun, Berta, Russiñol, Núria, Playa-Albinyana, Heribert, Baumann, Tycho, Duran-Ferrer, Martí, Kulis, Marta, Carbó-Meix, Anna, Mozas, Pablo, Alcoceba, Miguel, González, Marcos, Navarro-Bailón, Almudena, Colado, Enrique, Payer, Ángel R., Aymerich, Marta, Terol, María J., Lu, Junyan, Knisbacher, Binyamin A., Hahn, Cynthia K., Ruiz-Gaspà, Sílvia, Enjuanes, Anna, Wu, Catherine J., Getz, Gad, Zenz, Thorsten, López-Guillermo, Armando, Martín-Subero, José I., Colomer, Dolors, Delgado, Julio, Campo, Elías, Nadeu, Ferran, Fundación la Caixa, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Instituto de Salud Carlos III, European Commission, Generalitat de Catalunya, National Institutes of Health (US), National Cancer Institute (US), Centro de Investigación Biomédica en Red Cáncer (España), Ministerio de Universidades (España), Fundación Científica Asociación Española Contra el Cáncer, National Heart, Lung, and Blood Institute (US), American Association for Cancer Research, Lady Tata Memorial Trust, Institución Catalana de Investigación y Estudios Avanzados, Centro Esther Koplowitz, Syrykh, Charlotte, Pons-Brun, Berta, Russiñol, Núria, Playa-Albinyana, Heribert, Baumann, Tycho, Duran-Ferrer, Martí, Kulis, Marta, Carbó-Meix, Anna, Mozas, Pablo, Alcoceba, Miguel, González, Marcos, Navarro-Bailón, Almudena, Colado, Enrique, Payer, Ángel R., Aymerich, Marta, Terol, María J., Lu, Junyan, Knisbacher, Binyamin A., Hahn, Cynthia K., Ruiz-Gaspà, Sílvia, Enjuanes, Anna, Wu, Catherine J., Getz, Gad, Zenz, Thorsten, López-Guillermo, Armando, Martín-Subero, José I., Colomer, Dolors, Delgado, Julio, Campo, Elías, and Nadeu, Ferran

Abstract

Chronic lymphocytic leukemia (CLL) has high biological and clinical heterogeneity.1,2 A few prognostic factors are used in clinical practice, including immunoglobulin heavy-chain variable (IGHV) gene somatic hypermutation (SHM) status, chromosome aberrations, and gene mutations, which remain insufficient for personalized patient management.3,4 Recent studies have shown that expression of the immunoglobulin lambda light chain IGLV3-21 gene carrying an SHM-derived G>C mutation changing the glycine at position 110 to an arginine (IGLV3-21R110) defines a subset of CLL with an intermediate epigenetic profile and an aggressive clinical course.5,6 When occurring on the IGLV3-21∗01 or ∗04 alleles, the R110 mutation allows homotypic B-cell receptor (BCR) interactions, triggering cell-autonomous BCR signaling5,7 and/or facilitating T-cell–independent engagement with superantigen.8 IGLV3-21R110 has been detected in up to 6.5% of patients with CLL at diagnosis and in up to 25% of patients enrolled in clinical trials.5,6,9 We6 and others5 have shown that all CLL cases belonging to aggressive stereotyped subset #2 carried the IGLV3-21R110. Nonetheless, approximately half of IGLV3-21R110 CLL are not classified as stereotyped subset #2 but seem to have a similar clinical outcome,5,6 suggesting that the conventional stereotyped subset #2 classification might not completely recognize this clinically aggressive subgroup of CLL. In addition, IGLV3-21R110 seems to have a prognostic value independent of the IGHV gene SHM status and methylation–based epigenetic subtypes.5,6 However, further studies in independent cohorts are needed to support its application in clinical practice.1,2,10-12 The aim of this study was to assess the prognostic value of IGLV3-21R110 in large and independent population-based cohorts of patients with CLL.

Published
2023

35. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors

Author

Fundació La Marató de TV3, Fundación Científica Asociación Española Contra el Cáncer, Generalitat de Catalunya, Instituto de Salud Carlos III, European Commission, Centro Esther Koplowitz, Hospital Clínic de Barcelona, Mozas, Pablo, López, Cristina, Grau, Marta, Nadeu, Ferran, Clot, Guillem, Valle, Sara, Kulis, Marta, Navarro, Alba, Ramis-Zaldivar, Joan Enric, González-Farré, Blanca, Rivas-Delgado, Alfredo, Rivero, Andrea, Frigola, Gerard, Balagué, Olga, Giné, Eva, Delgado, Julio, Villamor, Neus, Matutes, Estella, Magnano, Laura, García-Sanz, Ramón, Huet, Sarah, Russell, Robert B., Campo, Elías, López-Guillermo, Armando, Beà, Sílvia, Fundació La Marató de TV3, Fundación Científica Asociación Española Contra el Cáncer, Generalitat de Catalunya, Instituto de Salud Carlos III, European Commission, Centro Esther Koplowitz, Hospital Clínic de Barcelona, Mozas, Pablo, López, Cristina, Grau, Marta, Nadeu, Ferran, Clot, Guillem, Valle, Sara, Kulis, Marta, Navarro, Alba, Ramis-Zaldivar, Joan Enric, González-Farré, Blanca, Rivas-Delgado, Alfredo, Rivero, Andrea, Frigola, Gerard, Balagué, Olga, Giné, Eva, Delgado, Julio, Villamor, Neus, Matutes, Estella, Magnano, Laura, García-Sanz, Ramón, Huet, Sarah, Russell, Robert B., Campo, Elías, López-Guillermo, Armando, and Beà, Sílvia

Abstract

While some follicular lymphoma (FL) patients do not require treatment or experience prolonged responses, others relapse early, and little is known about genetic alterations specific to patients with a particular clinical behavior. We selected 56 grade 1–3A FL patients according to their need of treatment or timing of relapse: never treated (n = 7), non-relapsed (19), late relapse (14), early relapse or POD24 (11), and primary refractory (5). We analyzed 56 diagnostic and 12 paired relapse lymphoid tissue biopsies and performed copy number alteration (CNA) analysis and next generation sequencing (NGS). We identified six focal driver losses (1p36.32, 6p21.32, 6q14.1, 6q23.3, 9p21.3, 10q23.33) and 1p36.33 copy-neutral loss of heterozygosity (CN-LOH). By integrating CNA and NGS results, the most frequently altered genes/regions were KMT2D (79%), CREBBP (67%), TNFRSF14 (46%) and BCL2 (40%). Although we found that mutations in PIM1, FOXO1 and TMEM30A were associated with an adverse clinical behavior, definitive conclusions cannot be drawn, due to the small sample size. We identified common precursor cells harboring early oncogenic alterations of the KMT2D, CREBBP, TNFRSF14 and EP300 genes and 16p13.3-p13.2 CN-LOH. Finally, we established the functional consequences of mutations by means of protein modeling (CD79B, PLCG2, PIM1, MCL1 and IRF8). These data expand the knowledge on the genomics behind the heterogeneous FL population and, upon replication in larger cohorts, could contribute to risk stratification and the development of targeted therapies.

Published
2023

36. IGLV3-21$^{R110}$ mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

Author

Nadeu, Ferran; https://orcid.org/0000-0003-2910-9440, Syrykh, Charlotte, Pons-Brun, Berta, Russiñol, Núria, Playa-Albinyana, Heribert; https://orcid.org/0000-0002-3447-3848, Baumann, Tycho Stephan, Duran-Ferrer, Martí; https://orcid.org/0000-0003-1666-5819, Kulis, Marta; https://orcid.org/0000-0001-8104-9620, Carbó-Meix, Anna, Mozas, Pablo; https://orcid.org/0000-0001-9528-4971, Alcoceba, Miguel, González, Marcos; https://orcid.org/0000-0001-6637-1072, Navarro-Bailón, Almudena; https://orcid.org/0000-0002-7972-5666, Colado, Enrique, Payer, Ángel, Aymerich, Marta, Terol, María José, Lu, Junyan; https://orcid.org/0000-0002-9211-0746, Knisbacher, Binyamin Asher; https://orcid.org/0000-0002-4962-9956, Hahn, Cynthia K; https://orcid.org/0000-0001-8284-7261, Ruiz-Gaspà, Sílvia, Enjuanes, Anna, Wu, Catherine J; https://orcid.org/0000-0002-3348-5054, Getz, Gad, Zenz, Thorsten; https://orcid.org/0000-0001-7890-9845, López-Guillermo, Armando, Martin-Subero, Jose I; https://orcid.org/0000-0001-8809-5195, Colomer, Dolors, Delgado, Julio; https://orcid.org/0000-0002-5157-4376, Campo, Elías; https://orcid.org/0000-0001-9850-9793, Nadeu, Ferran; https://orcid.org/0000-0003-2910-9440, Syrykh, Charlotte, Pons-Brun, Berta, Russiñol, Núria, Playa-Albinyana, Heribert; https://orcid.org/0000-0002-3447-3848, Baumann, Tycho Stephan, Duran-Ferrer, Martí; https://orcid.org/0000-0003-1666-5819, Kulis, Marta; https://orcid.org/0000-0001-8104-9620, Carbó-Meix, Anna, Mozas, Pablo; https://orcid.org/0000-0001-9528-4971, Alcoceba, Miguel, González, Marcos; https://orcid.org/0000-0001-6637-1072, Navarro-Bailón, Almudena; https://orcid.org/0000-0002-7972-5666, Colado, Enrique, Payer, Ángel, Aymerich, Marta, Terol, María José, Lu, Junyan; https://orcid.org/0000-0002-9211-0746, Knisbacher, Binyamin Asher; https://orcid.org/0000-0002-4962-9956, Hahn, Cynthia K; https://orcid.org/0000-0001-8284-7261, Ruiz-Gaspà, Sílvia, Enjuanes, Anna, Wu, Catherine J; https://orcid.org/0000-0002-3348-5054, Getz, Gad, Zenz, Thorsten; https://orcid.org/0000-0001-7890-9845, López-Guillermo, Armando, Martin-Subero, Jose I; https://orcid.org/0000-0001-8809-5195, Colomer, Dolors, Delgado, Julio; https://orcid.org/0000-0002-5157-4376, and Campo, Elías; https://orcid.org/0000-0001-9850-9793

Published
2023

38. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab.

Author

Ramsower, Colleen A., Rosenthal, Allison, Robetorye, Ryan S., Mwangi, Raphael, Maurer, Matthew, Villa, Diego, McDonnell, Tim, Feldman, Andrew, Cohen, Jonathon B., Habermann, Thomas, Campo, Elias, Clot, Guillem, Bühler, Marco M., Kulis, Marta, Martin‐Subero, Jose Ignacio, Giné, Eva, Cook, James R., Hill, Brian, Raess, Philipp W., and Beiske, Klaus H.

Subjects
MANTLE cell lymphoma, RITUXIMAB, OLDER patients, SURVIVAL rate, BIOMARKERS
Abstract

Summary: Mantle cell lymphoma (MCL) is clinically and biologically heterogeneous. While various prognostic features have been proposed, none currently impact therapy selection, particularly in older patients, for whom treatment is primarily dictated by age and comorbidities. Herein, we undertook a comprehensive comparison of clinicopathological features in a cohort of patients 60 years and older, uniformly treated with bendamustine and rituximab, with a median survival of >8 years. The strongest prognostic indicators in this cohort were a high‐risk call by a simplified MCL international prognostic index (s‐MIPI) (HR: 3.32, 95% CI: 1.65–6.68 compared to low risk), a high‐risk call by MCL35 (HR: 10.34, 95% CI: 2.37–45.20 compared to low risk) and blastoid cytology (HR: 4.21, 95% CR: 1.92–9.22 compared to classic). Patients called high risk by both the s‐MIPI and MCL35 had the most dismal prognosis (HR: 11.58, 95% CI: 4.10–32.72), while those with high risk by either had a moderate but clinically relevant prognosis (HR: 2.95, 95% CI: 1.49–5.82). A robust assay to assess proliferation, such as MCL35, along with stringent guidelines for cytological evaluation of MCL, in combination with MIPI, may be a strong path to risk‐stratify older MCL patients in future clinical trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Supplementary Table S1 from PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia

Author

Li, Jianping, primary, Hlavka-Zhang, Julia, primary, Shrimp, Jonathan H., primary, Piper, Crissandra, primary, Dupéré-Richér, Daphne, primary, Roth, Jacob S., primary, Jing, Duohui, primary, Casellas Román, Heidi L., primary, Troche, Catalina, primary, Swaroop, Alok, primary, Kulis, Marta, primary, Oyer, Jon A., primary, Will, Christine M., primary, Shen, Min, primary, Riva, Alberto, primary, Bennett, Richard L., primary, Ferrando, Adolfo A., primary, Hall, Matthew D., primary, Lock, Richard B., primary, and Licht, Jonathan D., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Methods and Figures from PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia

Author

Li, Jianping, primary, Hlavka-Zhang, Julia, primary, Shrimp, Jonathan H., primary, Piper, Crissandra, primary, Dupéré-Richér, Daphne, primary, Roth, Jacob S., primary, Jing, Duohui, primary, Casellas Román, Heidi L., primary, Troche, Catalina, primary, Swaroop, Alok, primary, Kulis, Marta, primary, Oyer, Jon A., primary, Will, Christine M., primary, Shen, Min, primary, Riva, Alberto, primary, Bennett, Richard L., primary, Ferrando, Adolfo A., primary, Hall, Matthew D., primary, Lock, Richard B., primary, and Licht, Jonathan D., primary

Published
2023
Full Text
View/download PDF

42. Data from PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia

Author

Li, Jianping, primary, Hlavka-Zhang, Julia, primary, Shrimp, Jonathan H., primary, Piper, Crissandra, primary, Dupéré-Richér, Daphne, primary, Roth, Jacob S., primary, Jing, Duohui, primary, Casellas Román, Heidi L., primary, Troche, Catalina, primary, Swaroop, Alok, primary, Kulis, Marta, primary, Oyer, Jon A., primary, Will, Christine M., primary, Shen, Min, primary, Riva, Alberto, primary, Bennett, Richard L., primary, Ferrando, Adolfo A., primary, Hall, Matthew D., primary, Lock, Richard B., primary, and Licht, Jonathan D., primary

Published
2023
Full Text
View/download PDF

43. Data from A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma

Author

Gómez, Soledad, primary, Garrido-Garcia, Alícia, primary, Garcia-Gerique, Laura, primary, Lemos, Isadora, primary, Suñol, Mariona, primary, de Torres, Carmen, primary, Kulis, Marta, primary, Pérez-Jaume, Sara, primary, Carcaboso, Ángel M., primary, Luu, Betty, primary, Kieran, Mark W., primary, Jabado, Nada, primary, Kozlenkov, Alexey, primary, Dracheva, Stella, primary, Ramaswamy, Vijay, primary, Hovestadt, Volker, primary, Johann, Pascal, primary, Jones, David T.W., primary, Pfister, Stefan M., primary, Morales La Madrid, Andrés, primary, Cruz, Ofelia, primary, Taylor, Michael D., primary, Martin-Subero, Jose-Ignacio, primary, Mora, Jaume, primary, and Lavarino, Cinzia, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Appendix from A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma

Author

Gómez, Soledad, primary, Garrido-Garcia, Alícia, primary, Garcia-Gerique, Laura, primary, Lemos, Isadora, primary, Suñol, Mariona, primary, de Torres, Carmen, primary, Kulis, Marta, primary, Pérez-Jaume, Sara, primary, Carcaboso, Ángel M., primary, Luu, Betty, primary, Kieran, Mark W., primary, Jabado, Nada, primary, Kozlenkov, Alexey, primary, Dracheva, Stella, primary, Ramaswamy, Vijay, primary, Hovestadt, Volker, primary, Johann, Pascal, primary, Jones, David T.W., primary, Pfister, Stefan M., primary, Morales La Madrid, Andrés, primary, Cruz, Ofelia, primary, Taylor, Michael D., primary, Martin-Subero, Jose-Ignacio, primary, Mora, Jaume, primary, and Lavarino, Cinzia, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Tables from A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma

Author

Gómez, Soledad, primary, Garrido-Garcia, Alícia, primary, Garcia-Gerique, Laura, primary, Lemos, Isadora, primary, Suñol, Mariona, primary, de Torres, Carmen, primary, Kulis, Marta, primary, Pérez-Jaume, Sara, primary, Carcaboso, Ángel M., primary, Luu, Betty, primary, Kieran, Mark W., primary, Jabado, Nada, primary, Kozlenkov, Alexey, primary, Dracheva, Stella, primary, Ramaswamy, Vijay, primary, Hovestadt, Volker, primary, Johann, Pascal, primary, Jones, David T.W., primary, Pfister, Stefan M., primary, Morales La Madrid, Andrés, primary, Cruz, Ofelia, primary, Taylor, Michael D., primary, Martin-Subero, Jose-Ignacio, primary, Mora, Jaume, primary, and Lavarino, Cinzia, primary

Published
2023
Full Text
View/download PDF

46. Epigenetic, psychological, and EEG changes after a 1-week retreat based on mindfulness and compassion for stress reduction: Study protocol of a cross-over randomized controlled trial

Author

Diez, Gustavo G., primary, Martin-Subero, Ignacio, additional, Zangri, Rosaria M., additional, Kulis, Marta, additional, Andreu, Catherine, additional, Blanco, Ivan, additional, Roca, Pablo, additional, Cuesta, Pablo, additional, García, Carola, additional, Garzón, Jesús, additional, Herradón, Carlos, additional, Riutort, Miguel, additional, Baliyan, Shishir, additional, Venero, César, additional, and Vázquez, Carmelo, additional

Published
2023
Full Text
View/download PDF

49. Supplementary Table S2 from PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia

Author

Jonathan D. Licht, Richard B. Lock, Matthew D. Hall, Adolfo A. Ferrando, Richard L. Bennett, Alberto Riva, Min Shen, Christine M. Will, Jon A. Oyer, Marta Kulis, Alok Swaroop, Catalina Troche, Heidi L. Casellas Román, Duohui Jing, Jacob S. Roth, Daphne Dupéré-Richér, Crissandra Piper, Jonathan H. Shrimp, Julia Hlavka-Zhang, and Jianping Li

Abstract

ALL patients with NSD2 mutations

Published
2023
Full Text
View/download PDF

50. Supplementary Methods and Figures from PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia

Author

Jonathan D. Licht, Richard B. Lock, Matthew D. Hall, Adolfo A. Ferrando, Richard L. Bennett, Alberto Riva, Min Shen, Christine M. Will, Jon A. Oyer, Marta Kulis, Alok Swaroop, Catalina Troche, Heidi L. Casellas Román, Duohui Jing, Jacob S. Roth, Daphne Dupéré-Richér, Crissandra Piper, Jonathan H. Shrimp, Julia Hlavka-Zhang, and Jianping Li

Abstract

Supplementary Methods and Figures

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results